Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The ACXP news feed on Stock Titan brings together company press releases, scientific updates and regulatory disclosures that highlight progress across its DNA polymerase IIIC (pol IIIC) inhibitor platform.
Readers can follow detailed announcements on ibezapolstat, Acurx’s lead oral Gram-Positive Selective Spectrum (GPSS®) antibiotic candidate for Clostridioides difficile Infection (CDI). News items include Phase 2 clinical data, preparations for international Phase 3 trials, and regulatory milestones such as FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations, EMA scientific advice, and a positive opinion from the EMA Paediatric Committee on the Pediatric Investigation Plan for ibezapolstat in children.
The ACXP news stream also covers developments in Acurx’s preclinical DNA pol IIIC pipeline, including patents granted in multiple jurisdictions for the ACX-375C program, collaborations with Leiden University Medical Center (LUMC) on structural biology of pol IIIC, and presentations at major scientific meetings like IDWeek and other infectious disease conferences. These updates often describe new data on microbiome selectivity, bile acid profiles, and potential class effects across the company’s inhibitor series.
Investors and observers can track capital markets and corporate actions reported by Acurx, such as warrant inducement transactions, equity line financings, and a 1-for-20 reverse stock split undertaken to support continued Nasdaq listing. For anyone monitoring antibiotic innovation against Gram-positive priority pathogens, the ACXP news page provides an organized view of Acurx’s clinical, regulatory, scientific and financing milestones over time.
Acurx Pharmaceuticals (Nasdaq: ACXP) announced a $500,000 grant from Health Holland to support a collaborative research project with Leiden University Medical Center. This project aims to explore the structure of DNA polymerase C from multi-drug resistant bacteria, enhancing the development of new antibiotics. Acurx will begin a Phase 2b clinical trial for Clostridioides difficile Infection (CDI) in late 2021, following promising results from an earlier trial where 100% of patients achieved primary efficacy endpoints. The research may lead to innovative treatments for serious Gram-positive pathogens.
Acurx Pharmaceuticals (NASDAQ: ACXP) will release its Q2 2021 financial results on August 17, 2021, at 8:30 a.m. ET. A conference call will be hosted by President David P. Luci and CFO Robert G. Shawah to discuss these results and provide a business update. The company is developing ibezapolstat, a novel oral antibiotic for C. difficile infection, which has received FDA designations as a Qualified Infectious Disease Product and Fast Track designation. Acurx plans to enroll in a Phase 2b efficacy study by the end of 2021.
Acurx Pharmaceuticals (NASDAQ: ACXP) filed a provisional patent for ibezapolstat, targeting Clostridioides difficile Infection (CDI) and aiming to improve gut microbiome health. Following a successful Phase 2a trial with a 100% clinical cure rate, Acurx will initiate a Phase 2b trial later this year. The company's approach focuses on dual-action therapy, potentially enhancing patient outcomes and reducing recurrence rates. The announcement reflects Acurx's commitment to protecting its antimicrobial technologies.
Acurx Pharmaceuticals (Nasdaq ACXP) announced promising results for ibezapolstat in preventing Clostridioides difficile Infection (CDI) recurrence during the World Microbe Forum 2021. Utilizing specimens from a Phase 1 trial, analysis indicates ibezapolstat may lower CDI recurrence risk compared to vancomycin. Dr. Kevin Garey highlighted its unique microbiome impact, suggesting a restorative effect. Acurx plans to further validate these findings in a Phase 2b trial. CDI remains a serious health issue, with approximately 600,000 infections annually in the U.S.
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) has successfully closed its initial public offering, selling 2,875,000 shares at $6.00 each, including an option for underwriters to purchase 375,000 additional shares. The offering generated approximately $14.8 million in net proceeds for the company. The SEC declared the registration statement effective on June 24, 2021. Acurx focuses on developing new antibiotics targeting difficult-to-treat bacterial infections.
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) announced the pricing of an underwritten initial public offering of 2,500,000 shares at $6.00 per share, aiming to raise approximately $15 million. The offering includes a 45-day option for underwriters to purchase an additional 375,000 shares. The proceeds will fund a Phase 2b clinical trial for ibezapolstat and pre-clinical development of ACX-375C, alongside general corporate purposes. Trading is set to begin on June 25, 2021, with the closing expected on June 29, 2021, subject to customary conditions.